September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Desmin is a Novel Druggable Regulator of Corneal Fibrosis
Author Affiliations & Notes
  • Alexandra Pietraszkiewicz
    Neuroscience, University of Connecticut Health Center, Southington, Connecticut, United States
  • Christopher Hampton
    Neuroscience, University of Connecticut Health Center, Southington, Connecticut, United States
  • Ling Lei
    Neuroscience, University of Connecticut Health Center, Southington, Connecticut, United States
  • Paola Bargagna-Mohan
    Neuroscience, University of Connecticut Health Center, Southington, Connecticut, United States
  • Royce Mohan
    Neuroscience, University of Connecticut Health Center, Southington, Connecticut, United States
  • Footnotes
    Commercial Relationships   Alexandra Pietraszkiewicz, None; Christopher Hampton, None; Ling Lei, None; Paola Bargagna-Mohan, University of Kentucky Research Foundation (P); Royce Mohan, University of Kentucky Research Foundation (P)
  • Footnotes
    Support  NIH Grant EY016782
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 1283. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Alexandra Pietraszkiewicz, Christopher Hampton, Ling Lei, Paola Bargagna-Mohan, Royce Mohan; Desmin is a Novel Druggable Regulator of Corneal Fibrosis. Invest. Ophthalmol. Vis. Sci. 2016;57(12):1283.

      Download citation file:


      © 2017 Association for Research in Vision and Ophthalmology.

      ×
  • Supplements
Abstract

Purpose : The intermediate filaments (IFs) vimentin and desmin are coordinately upregulated in myofibroblasts during corneal fibrosis and their downregulation by the potent IF-targeting drug withaferin A (WFA) is protective against fibrosis and haze (JBC 2012, 287: 989-1006). In this study, we have employed mice deficient for desmin to unravel how desmin contributes to corneal fibrosis.

Methods : Wild-type (WT) 129Svev litter mates, desmin hemizygous (Des+/-) and homozygous (Des-/-) knockout mice were employed. Mice were anesthetized by intraperitoneal injection of ketamine and xylazine, and corneas were anesthetized with proparacain eye drop. A 1 μl drop of dilute 0.15 M NaOH was applied for 1 minute, the cornea was washed with saline solution, and the corneal and limbal epithelium was removed by scraping with a blunt Tooke corneal knife. After 7, 14 or 30 days of recovery, mouse corneas were assessed for corneal opacity and mice sacrificed. The enucleated eyes were either cryosectioned for immunohistochemistry (IHC) or corneas dissected and subjected to western blot (WB) analysis. In other studies, injured Des-/- mice were also treated with vehicle or 2 mg/kg/d WFA for 14 days.

Results : We discovered that the injured corneas of Des-/- mice like those of WT mice lose corneal transparency and become fibrotic. Surprisingly, Des+/- corneas were protected against corneal fibrosis and revealed absence of a-smooth muscle actin and vimentin upregulation in repairing stromal cells. Recently, we showed that vimentin becomes phosphorylated at serine 38 residue (pSer38Vim) and the expression of this biomarker is correlated with corneal fibrosis (PlosOne 2015, 10(7):e0133399). Therefore, we investigated the expression of pSer38Vim in corneas of desmin-deficient mice. We discovered that the healing Des+/- corneas, unlike fibrotic Des-/- or WT corneas, show very low expression levels of pSer38Vim. The expression of pSer38vim was also altered in Des-/- corneas by treatment with WFA.

Conclusions : Vimentin and desmin play overlapping roles in wound repair and fibrosis, however, depending of gene dosage, the degree of desmin loss can have protective or pathological consequences. Our studies, for the first time, illuminates that the phosphorylation status of vimentin is also governed by desmin during wound repair, and that targeting of pSer38vim by WFA in desmin deficiency can prevent corneal fibrosis.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×